The Twenty-Third International Conference on Antiviral Research

Sponsored by

The International Society For Antiviral Research

Hyatt Regency San Francisco

San Francisco, California, USA

April 25–April 28, 2010

Table of Contents
	Page
ISAR Organization and ISAR Conference and Program Committees
Organizing Secretariats
ISAR/ICAR Corporate Sponsors
Keynote Address, Mini-Symposia and Social Functions
Scientific Program
Sunday, April 25, 2010
Drug Discovery and Development 101
Keynote Address
Monday, April 26, 2010
Oral Session 1: Mini-Symposium: Antiviral Drug Resistance
Oral Session 2: Hepatitis Viruses
Poster Session 1: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods
Tuesday, April 27, 2010
Oral Session 3: Retroviruses and Herpesviruses
Clinical Symposium
Poster Session 2: Herpesviruses, Poxviruses, Other Antiviral Agents, Medicinal Chemistry, Animal Models and Topical Microbicides
Wednesday, April 28, 2010
Oral Session 4: Mini-Symposium: Prodrug Chemistry and Antiviral Drug Development
Invitation to 24th ICAR and ISAR Business Meeting
Oral Session 5: Respiratory Viruses, Emerging Viruses and Biodefense
Shotgun Poster Session
Abstracts
Complete Author Index
Invitation to the 24th International Conference on Antiviral Research
Locations for Future International Conferences on Antiviral Research

Organization

International Society for Antiviral Research

and

Twenty-Third International Conference on Antiviral Research

Officers

President – Amy K. Patick, San Diego, California, USA

President-Elect – Joseph M. Colacino, South Plainfield, New Jersey, USA

Secretary – Susan Cox, Melbourne, Australia

Treasurer – Dale L. Barnard, Logan, Utah, USA

Past President – Christopher McGuigan, Cardiff, Wales, UK

ISAR Conference and Program Committees

Conference Chair: Joseph Colacino, South Plainfield, New Jersey, USA

Program Chair: Robert W. Buckheit, Jr., Frederick, Maryland, USA

John A. Secrist III, Birmingham, Alabama, USA

John C. Drach, Ann Arbor, Michigan, USA

José A. Esté, Barcelona, Spain

Charles E. McKenna, Los Angeles, California, USA

Chris Meier, Heidelberg, Germany

Amy K. Patick, Escondido, California, USA

Karen K. Biron, Research Triangle Park, North Carolina, USA

Donald Smee, Logan, Utah, USA

John Morrey, Logan, Utah, USA

Richard Whitley, Birmingham, Alabama, USA

Mike Bray, Bethesda, Maryland, USA

Tomas Cihlar, Foster City, California, USA

Johan Neyts, Leuven, Belgium

Organizing Secretariats
Courtesy Associates	Joseph Colacino
2025 M Street, NW	PTC Therapeutics, Inc.
Suite 800	100 Corporate Court
Washington, DC 20036	South Plainfield, NJ 07080
USA	USA
Phone: +1 202 973 8690	Phone +1 908 912 9131
Fax: +1 202 331 0111	Fax: +1 908 222 0567
E-mail: isar@courtesyassoc.com	E-mail: jcolacino@ptcbio.com

The International Society For Antiviral Research (ISAR)

The Society was organized in 1987 as a non-profit scientific organization for the purpose of advancing and disseminating knowledge in all areas of antiviral research. To achieve this objective, the Society organizes an annual meeting. The Society is now in its twenty fourth year of existence, and has about 550 members representing 30 countries. For membership application forms or further information, please contact Dr. Susan Cox, Secretary, ISAR; Senior Vice President, Drug Development, Avexa Ltd., 576 Swan Street, Richmond, VIC 3121, Australia, telephone +61 3 9208 4066; fax +61 3 9208 4004; E-mail: scox@avexa.com.au. Membership application forms will also be available at the Conference Registration desk, or from our website www.isar-icar.com.

Contributors to the 23rd International Conference on Antiviral Research

Platinum

Gilead Sciences, Inc., Foster City, CA, USA

Gold

Chimerix, Inc., Durham, NC, USA

GlaxoSmithKline, Inc., Research Triangle Park, NC, USA

Southern Research Institute, Birmingham, AL, USA

Silver

Anadys Pharmaceuticals, Inc., San Diego, CA, USA

Boehringer Ingelheim (Canada) Ltd., Laval, Quebec, Canada

Idenix Pharmaceuticals, Inc., Cambridge, MA, USA

NanoViricides, Inc., West Haven, CT, USA

Pharmasset, Inc., Princeton, NJ, USA

Roche Palo Alto, LLC, Palo Alto, CA, USA

Vertex Pharmaceuticals, Inc., Cambridge, MA, USA

Bronze

Abbott Laboratories, Inc., Abbott Park, IL, USA

Adamas Pharmaceuticals, Inc., Emeryville, CA, USA

AiCuris GmbH & Co. KG, Wuppertal, Germany

Apath, LLC, Brooklyn, NY, USA

Avexa Ltd., Richmond, Victoria, Australia

Biota Holdings Ltd., Notting Hill, Victoria, Australia

Debiopharm S.A., Lausanne, Switzerland

Elsevier B.V., Amsterdam, The Netherlands

Inhibitex, Inc., Alpharetta, GA, USA

InterMune, Inc., Brisbane, CA, USA

Medivir AB, Huddinge, Sweden

Microbiotix, Inc., Worcester, MA, USA

Novartis AG, Basel, Switzerland

PTC Therapeutics, Inc., South Plainfield, NJ, USA

Susavion Biosciences, Inc., Tempe, AZ, USA

Toyama Chemical Co., Ltd., Tokyo, Japan

Vical, Inc., San Diego, CA, USA

4SC AG, Planegg-Martinsried, Germany

Additional Support Provided by:

Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA

KEYNOTE ADDRESS

“Recent Progress in the Simplification of HIV Therapy ad Future Prospects”

John Martin, Ph.D.

Sunday, April 25, 2010

5:00–6:00 p.m.

MINI-SYMPOSIA
“Antiviral Drug Resistance”	“Clinical Update on Antiviral Drugs”
Monday, April 26, 2010	Tuesday, April 27, 2010
8:00 a.m.–12:00 p.m.	1:00–4:00 p.m.

“Prodrug Chemistry and Antiviral Drug Development”

Wednesday, April 28, 2010

8:00 a.m.–12:00 p.m.

SOCIAL EVENTS

Opening Reception

with light hors d’oeuvres

Sunday, April 25, 2010

6:00–8:00 p.m.

Conference Banquet

Tuesday, April 27, 2010

Reception 7:30 p.m.

Dinner and Program 8:00–10:00 p.m.

All Scientific and Social Events will be held in the Hyatt Regency San Francisco

Final Program

Twenty-Third International Conference on Antiviral Research

Sponsored by the

International Society for Antiviral Research

Hyatt Regency San Francisco

San Francisco, California, USA

April 25–April 28, 2010

Sunday, April 25, 2010
Drug Discovery and Development 101
Chair(s): Joe Colacino, Ph.D. and Amy Patick, Ph.D.
Grand A
01:00 p.m.–04:00 p.m.
13:00	1.	Nonclinical Toxicology Safety Assessment of Antiviral Therapeutics
		Anne Chester
		Gilead Sciences, USA
13:45	2.	Computational Chemistry in Drug Discovery
		Ken Brameld, Ph.D.
		Roche Palo Alto, LLC USA
14:30	3.	Navigating the Regulatory Challenges in Drug Development
		Natalie McClure, Ph.D.
		Adamas Pharmaceuticals, Inc., USA
Opening Greetings
Grand A
04:45 p.m.–05:00 p.m.
16:45		Welcome to the 23rd ICAR
		Amy Patick, Ph.D.
		President, ISAR
16:50		Welcome to San Francisco
		Joe Colacino, Ph.D.
		Chair, ICAR Conference Committee
16:55		Introduction of the Keynote Speaker
		Joseph Colacino, Ph.D.
		President-Elect, ISAR
Keynote Address
Chair(s): Joe Colacino, Ph.D.
Grand A
05:00 p.m.–06:00 p.m.
	4.	Recent Progress in the Simplification of HIV Therapy and Future Prospects
		John Martin
		Gilead Sciences, Inc., USA
Opening Reception
Atrium 2–5
06:00 p.m.–08:00 p.m.
Monday, April 26, 2010
Oral Session 1: Mini-Symposium: Antiviral Drug Resistance
Chair(s): Samuel Broder, M.D. and Jose Este, Ph.D.
Grand A
08:00 a.m.–12:00 p.m.
08:15	5.	Confronting HIV Drug Resistance
		Douglas Richman, M.D.
		University of California at San Diego, USA
09:00	6.	Emergence of Resistance to HCV Direct Acting Antivirals and Potential Therapeutic Implications
		Isabel Najera, Ph.D.
		Roche Palo Alto LLC, USA
09:45		Break
10:15	7.	Expending the Capability of HIV Drug Resistance Assays to New Drug Targets, HCV, and Influenza
		Christos Petropolous, Ph.D.
		Monogram Biosciences, Inc., USA
10:45	8.	Next Generation Sequencing Insights into Virus Quasispecies
		Robert Shafer, Ph.D.
		Stanford University, USA
11:15	9.	Influenza Antiviral Resistance: Epidemiologic and Clinical Implications
		Frederick Hayden
		University of Virginia, USA; World Health Organization, Switzerland
Elion Award Lecture
Grand A
01:00 p.m.–02:00 p.m.
13:00		Presentation of Elion Award
		Amy Patick, Ph.D.
		President, ISAR
13:15	10.	Uncommon Combinations
		Bo Oberg, Ph.D.
		Medivir AB, Huddinge, Sweden
Oral Session 2: Hepatitis Viruses
Chair(s): Phillip Furman, Ph.D. and Klaus Klumpp, Ph.D.
Grand A
02:00 p.m.–04:00 p.m.
14:00	11.	Diphenylcarboxamides as Inhibitors of HCV Non-structural Protein NS5A
		Malcolm Carter, Bob Baxter, David Bushnell, Stuart Cockerill, Jo Chapman, Sally Fram, Emma Goulding, Mike Lockyer, Neil Mathews, Pilar Najarro, Dilupa Rupassara, James Salter, Elaine Thomas, Chris Wheelhouse, Jessica Borger, Kenneth Powell
		Arrow Therapeutics, London, United Kingdom
14:15	12.	Selection of Clinically Relevant Protease Inhibitor Resistant Viruses using the HCV Infection System
		Guofeng Cheng, Katie Chan@gilead.com, Huiling Yang, Amy Corsa, Maria Pokrovskii, Matthew Paulson, Margaret Robinson, Gina Bahador, Weidong Zhong, William Delaney
		Gilead Sciences, Foster City, CA, USA
14:30	13.	In Vitro Selection and Characterization of Hepatitis C Virus Replicons Double or Triple Resistant to Various Non-nucleoside HCV Polymerase Inhibitors
		Leen Delang, Inge Vliegen, Pieter Leyssen, Johan Neyts
		Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium
14:45	14.	Identification and Characterization of a Hepatitis C Virus Capsid Assembly Inhibitor
		Juliane Gentzsch1, Clarence R. Hurt2, Vishwanath R. Lingappa2, Thomas Pietschmann1
		1Division of Experimental Virology, TWINCORE, Hannover, Germany; 2Prosetta Bioconformatics, San Francisco, CA, USA
15:00	15.	The Requirement of HCV NS3 Oligomerization for RNA Helicase Activity is RNA Substrate Dependent
		Julie Hang, Yanli Yang, Junjun Gao, Vincent Leveque, Marie Dinh, Mohammad Hekmat-Nejad, George Stepan, Phil Kobel, Klaus Klumpp
		Roche, Palo Alto, CA, USA
15:15	16.	Bound Structure and Biochemical Mechanism of Action of BI 201335, A Potent, Non-covalent Inhibitor of HCV NS3-NS4A Protease
		Christopher T. Lemke, Songping Zhao, Nathalie Goudreau, Oliver Hucke, Diane Thibeault, Montse Llinàs-Brunet, Peter W. White
		Boehringer Ingelheim (Canada) Ltd., Laval, QC, Canada
15:30	17.	MK-5172, A Novel Macrocyclic Inhibitor of NS3/4A Protease Demonstrates Efficacy against Viral Resistance in the Chimpanzee Model of Chronic Hepatitis C Virus Infection
		Steve Ludmerer1, Steve Carroll2, John McCauley3, Mike Rudd3, Paul Coleman3, Nigel Liverton3, Christine Burlein2, Jill DiMuzio2, Adam Gates2, Don Graham1, Carolyn McHale1, Mark Stahlhut2, Christine Fandozzi4, Daria Hazuda2, Joe Vacca1, David Olsen2
		1Department of Antiviral Research, Merck-Frosst Research Laboratories, Kirkland, QC, Canada; 2Department of Antiviral Research, Merck Research Labs, West Point, PA, USA; 3Department of Medicinal Chemistry, Merck Research Labs, West Point, PA, USA; 4Department of Drug Metabolism, Merck Research Labs, West Point, PA, USA
15:45	18.	Late Breaker Presentation
Tuesday, April 27, 2010
Prusoff Young Investigator Award Lecture
Grand A
08:00 a.m.–09:00 a.m.
08:00		Presentation of Prusoff Award
		Amy Patick, Ph.D.
		President, ISAR
08:15	19.	Coreceptors and Cellular Factors as Targets for Antiviral Drugs
		Jose Este, Ph.D.
		Fundacio Irsicaixa, Barcelona, Spain
Oral Session 3: Retroviruses and Herpesviruses
Chair(s): Rhonda Cardin, Ph.D. and Masanori Baba, Ph.D.
Grand A
09:00 a.m.–11:30 a.m.
09:00	20.	Identification of a N-linked Glycan on HIV-1 gp120 that is Indispensable for Viral Entry
		Katrien François, Jan Balzarini
		Rega Institute for Medical Research, K.U.Leuven, B-3000 Leuven, Belgium
09:15	21.	Protein–Protein Interactions Occurring during HIV Capsid Assembly in a Cell-free Protein Synthesizing System
		Kiel Copeland1, William Hansen1, Vinod Asundi1, Shi Hong1, James Chamberlin1, Debendranath Dey1, Sean Broce1, Harold Himmel1, Caleb Decloutte1, Salvin Ram1, Imke Steffen2, Stefan Pöhlmann2, Jaisri R. Lingappa3, Clarence R. Hurt1, Vishwanath R. Lingappa1
		1Prosetta Bioconformatics, Inc., San Francisco, CA, USA; 2Institute of Virology Hannover Medical School, Hannover, Germany; 3Deptartment of Global Health, University of Washington, Seattle, WA, USA
09:30		Break
10:00	22.	An Intrabody based on a Llama Single-Domain Antibody Targeting the N-terminal α-Helical Multimerization Domain of HIV-1 Rev Inhibits Viral Replication
		Dirk Daelemans1, Thomas Vercruysse1, Els Pardon2, Els Vanstreels1, Jan Steyaert2
		1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Structural Biology Brussels, Department of Molecular Interactions, VUB, Brussels, Belgium
10:15	23.	Discovery of GS-9350: A Novel and Selective Pharmacoenhancer without Anti-HIV Activity
		L. Xu, H. Liu, B. Murray, C. Callebaut, A. Hong, R. Vivian, M. Lee, L. Tsai, K. Stray, J. Chau, R. Strickley, J. Koziara, Y. Choi, G. Rhodes, M. Desai
		Gilead Sciences, Foster City, CA, USA
10:30	24.	Protection against Genital HSV-2 in Guinea Pigs with Subunit Vaccines Containing gD2, gB2, and gH/gL glycoprotein antigens complexed with CLDC Adjuvant
		R.D. Cardin1, F.J. Bravo1, J.D. Earwood1, J.R. Clark1, R.J. Eisenberg2, G.H. Cohen2, J. Fairman3, D.I. Bernstein1
		1Cincinnati Children's Hosp, Cincinnati, OH, USA; 2Univ. of Penn, Philadelphia, PA, USA; 3Juvaris BioTherapeutics, Inc., Pleasanton, CA, USA
10:45	25.	In Vitro and In Vivo Activities of the Novel Anti-Cytomegalovirus Compound AIC246
		Peter Lischka1, Guy Hewlett2, Tobias Wunberg3, Judith Baumeister4, Daniela Paulsen1, Thomas Goldner1, Helga Ruebsamen-Schaeff1, Holger Zimmermann1
		1AiCuris GmbH&Co.KG, Wuppertal, Germany; 2HBSC, Wuppertal, Germany; 3Boehringer Ingelheim RCV GmbH&CoKG, Vienna, Austria; 4Ablynx N.V., Zwijnaarde-Gent, Belgium
11:00	26.	A Chimeric Guinea Pig Cytomegalovirus (GPCMV) Encoding Wild Type or Mutant HCMV UL97 Renders GPCMV Susceptible or Resistant to Ganciclovir while Retaining an Ability to Disseminate in the Animal Host
		Alistair McGregor, Jared Leibelt, Catherine Bouska, Mark Schleiss
		University of Minnesota, Minneapolis, MN, USA
11:15	27.	Late Breaker Presentation
Clinical Symposium
Chair(s): Paul Griffiths, M.D. and Richard Whitley, M.D.
Grand A
01:00 p.m.–04:00 p.m.
Reception
Grand Foyer
07:00 p.m.–07:30 p.m.
ICAR Banquet and Program
Grand A
07:30 p.m.–09:30 p.m.
Wednesday, April 28, 2010
Oral Session 4: Mini-Symposium: Prodrug Chemistry and Antiviral Drug Development
Chair(s): Karl Y. Hostetler, M.D. and Adrian S. Ray, Ph.D.
Grand A
08:00 a.m.–12:00 p.m.
08:00	28.	IDX-184—A Novel, Liver-targeted, Once-A-Day Nucleotide Prodrug for the Treatment of Chronic HCV Infection
		David Standring, Ph.D.
		Idenix, Inc., USA
08:30	29.	CMX157: Design and Development of Hexadecyloxypropyl Cidofovir and Tenofovir
		Randall Lanier, Ph.D.
		Chimerix, Inc., USA
09:00	30.	Altering the Chemistry of Alkoxyalkyl Prodrugs of Acyclic Nucleoside Phosphonates: New Directions and Novel Applications
		Karl Hostetler
		University of California at San Diego, USA
09:30		Break
10:00	31.	Nucleoside Phosphonate Prodrugs: From Improved Oral Bioavailability to Target Tissue Enrichment
		Adrian Ray
		Gilead Sciences, Inc., USA
10:30	32.	PSI-7851: From Discovery to the Clinic
		Phillip Furman
		Pharmasset, Inc., USA
11:00	33.	Breaking the Rules: Selection of a Prodrug Clinical Candidate for HCV Therapy
		Geoff Henson, Ph.D.
		Inhibitex, Inc., USA
Oral Session 5: Respiratory Viruses, Emerging Viruses and Biodefense
Chair(s): Graciela Andrei, Ph.D. and Peter Silvera, Ph.D.
Grand A
01:00 p.m.–05:30 p.m.
13:00	34.	PLENARY: Celebrating AZT! Antiretroviral Drugs: From Bench to Bedside to the World.
		Samual Broder, M.D.
		Celera Genomics, Inc., USA
13:45	35.	ST-246, A Therapeutic for Smallpox
		Tahar Babas1, Deborah Sites1, Lourdes Nieves-Duran1, Amy Sands1, Rhonda Wright1, Amy Rippeon1, Dawn Golightly1, Ginger Donnelly1, Lowrey Rhodes1, Robert Jordan2, Dennis Hruby2, Peter Silvera1
		1Southern Research Institute, Frederick, MD, USA; 2SIGA Technologies, Corvalis, OR, USA
14:00	36.	Evidence for Host Drug Targets Essential for Dengue Virus Capsid Formation.
		Marissa Baker-Wagner1, Nicole Wolcott2, Yoko Marwidi1, Shao Feng Yu1, Debendranath Dey1, Bruce Onisko1, Katie Barlow1, Shalini Potluri1, Christine Sahlman1, Alfredo Calayag1, Vishwanath R. Lingappa1, Pamela Glass3, Michael Farmer1, Clarence R. Hurt1, William Hansen1
		1Prosetta Bioconformatics, Inc., San Francisco, CA, USA; 2CUBRC, Inc., Buffalo, NY, USA; 3Virology Division, USAMRIID, Ft Detrick, MD, USA
14:15	37.	An Adenosine Nucleoside Inhibitor of Dengue Virus.
		Wouter Schul, Yen-Liang Chen, Zheng Yin, Thomas Keller, Pei-Yong Shi
		Novartis Institute for Tropical Diseases, Singapore, Singapore
14:30	38.	Small Molecule Agonists of the RIG-I Pathway and their Potent Antiviral Actions
		Kristin Bedard1, Nicholas Pointinger1, Eric Tarcha1, Michael Katze2, Michael Gale Jr.2, Shawn Iadonato1
		1Kineta, Inc., Seattle, WA, USA; 2University of Washington, Seattle, WA, USA
14:45	39.	The NF-KappaB-Inhibitor SC75741 Efficiently Blocks Influenza Virus Propagation by Retention of the Viral RNP Complexes in the Nucleus without the Tendency to Induce Resistant Virus Variants
		Christina Erhardt1, Andrea Rückle1, Karoline Droebner2, Eike Hrincius1, Oliver Planz2, Stephan Ludwig1
		1FLI, Tuebingen, Germany; 2IMV/ZMBE, Muenster, Germany
15:00	40.	The Triple Combination Antiviral Drug (TCAD) Regimen of Amantadine, Ribavirin, and Oseltamivir is Highly Efficacious Against Susceptible and Resistant Influenza Virus Strains in Mouse Treatment Models
		Matthew Gross1, Minh Le1, Donald Smee2, Dale Barnard2, Amy Patick1, Jack Nguyen1
		1Adamas Pharmaceuticals, Emeryville, CA, USA; 2Utah State University, Logan, UT, USA
15:15	41.	In Vitro and In Vivo Efficacy of Combinational Therapy with Favipiravir (T-705) and Oseltamivir against Influenza A/CA/04/09 Pandemic H1N1 Virus
		Dale Barnard1, Yousuke Furuta2, Klaus Klummp3, Donald Smee1, John Morrey1, Bart Tarbet1
		1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2Toyama Chemical Co., Ltd., Tokyo, Japan; 3Roche Palo Alto LLC, Palo Alto, CA, USA,
15:30		Invitation to 24th ICAR, Sofia, Bulgaria
		Angel Galabov, Ph.D.
		Host, 24th ICAR
15:45		ISAR Business Meeting
16:00		Break
16:15	42.	Antiviral Activity of Leflunomide against Respiratory Syncytial Virus
		Melinda Dunn, Deborah Knight, W. James Waldman
		Department of Pathology, The Ohio State University, Columbus, OH, USA
16:30	43.	Small-molecule Inhibition of Respiratory Syncytial Virus Fusion: It takes Two to Tango
		Dirk Roymans1, Eric Arnoult2, Maxwell D. Cummings1, Anil Koul3, Koen Andries4
		1Tibotec-Virco Virology BVBA, Mechelen, Belgium; 2Tibotec, A Division of Janssen-Cilag, Val de Reuil Cedex, France; 3Tibotec-Virco Virology BVBA, Beerse, Belgium; 4J&JPRD, Beerse, Belgium
16:45	44.	Enterovirus 3C Proteases: Structure-based Discovery of Inhibitors
		Rolf Hilgenfeld
		University of Luebeck, Luebeck, Germany
17:00	45.	A Novel 9-Arylpurine Acts as a Selective Inhibitor of In vitro Enterovirus Replication Possibly by Targeting Virus Encapsidation
		Hendrik Jan Thibaut1, Lonneke van der Linden2, Jan Paeshuyse1, Armando De Palma1, Leire Aguado3, Frank Van Kuppeveld2, María-Jesús Pérez-Pérez3, Johan Neyts1
		1Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium; 2Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands; 3Instituto de Química Médica (CSIC), Madrid, Spain
17:15	46.	Is the Large T Antigen: A Target for the Inhibition of SV40 Replication?
		Dimitri Topalis, Ilya Lebeau, Pierre Fiten, Ghislain Opdenakker, Graciela Andrei, Robert Snoeck
		Rega Institute for Medical Research, Leuven, Belgium
Poster Session 3: Shotgun Poster Presentations
Chair(s): Mark Prichard, Ph.D. and Johan Neyts, Ph.D.
Grand A
05:30 p.m.–06:30 p.m.
Monday, April 26, 2010
Poster Session 1: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods
Pacific D-O
04:00 p.m.–06:00 p.m.
	47.	Studies of HIV-1 Integrase Inhibitory Activity of Wrightia tinctoria
		Periyasamy Selvam1, Kasthuraiah Maddali2, Yves Pommier2
		1Devaki Amma Memorial College of Pharmacy, Chelembra, Malapuram, India; 2Laboratory of Molecular Pharmacology, National Cancer Institute, NIH, Bethesda, Maryland 20892, MD, USA
	48.	Preliminary Evidence of Rapid HBsAg Seroconversion in Patients with Chronic Hepatitis B (CHB) Treated with a DNA-based Amphipathic Polymer
		Mamun Al-Mahtab1, Michel Bazinet2, Andrew Vaillant2
		1Sheikh Mujib Medical University, Dhaka, Bangladesh; 2REPLICor Inc., Montreal, QC, Canada
	49.	γ-Carboline Derivatives as Potent and Selective Inhibitors of Bovine Viral Diarrhea Virus (BVDV) Replication.
		Masanori Baba1, Mohammed Salim1, Mika Okamoto1, Hiroshi Aoyama2, Yuichi Hashimoto2, Yutaka Takebe3, Jan Paeshuyse4, Johan Neyts4
		1Kagoshima University, Kagoshima, Japan; 2The University of Tokyo, Tokyo, Japan; 3National Institute of Infectious Diseases, Tokyo, Japan; 4Katholieke Universiteit Leuven, Leuven, Belgium
	50.	Combination of Peramivir and Rimantadine Demonstrate Synergistic Interaction in Influenza A Mouse Model
		Shanta Bantia, Debra Kellogg, Cynthia Parker, YuHong Luo, Y.S. Babu
		BioCryst Pharmaceuticals, Inc., Birmingham, AL, USA
	51.	A Single Intramuscular Injection of Peramivir Demonstrates Anti-influenza Activity against Recently Isolated Pandemic Flu Virus H1N1 (A/CA/04/2009)
		Shanta Bantia1, Debra Kellogg1, Cynthia Parker1, Ramanda Upshaw1, Natalia Ilyushina2, Mark Prichard3, Y.S. Babu1
		1BioCryst Pharmaceuticals, Inc., Birmingham, AL, USA; 2St. Jude's Children's Research Hospital, Memphis, TN, USA; 3University of Alabama at Birmingham, Birmingham, AL, USA
	52.	In Vitro Dose Ranging Studies for Serine Protease Inhibitor, MK-4519, against a Hepatitis C Virus (HCV) Replicon using the BelloCell System
		Ashley N. Brown1, D.V. Singer1, J.J. McSharry1, R.J.O. Barnard2, D.J. Hazuda2, G.L. Drusano1
		1Ordway Research Institute, Albany, NY, USA; 2Merck Research Labs, West Point, PA, USA
	53.	Maporal Hantavirus β-Integrin Utilization and Sensitivity to Favipiravir
		Kristin Buys1, Kie-Hoon Jung1, Yousuke Furuta2, Brian Gowen1
		1Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences at Utah State University, Logan, UT, USA; 2Research Laboratories, Toyama Chemical Company, Ltd., Toyama, Japan
	54.	Small Molecule Inhibitors of Dengue Virus Replication are Active In Vivo
		Chelsea Byrd, Chris Harver, Kara Cardwell, Doug Grosenbach, Aklile Berhanu, Dongcheng Dai, Dennis Hruby, Robert Jordan
		SIGA Technologies, Corvallis, OR, USA
	55.	Biological Profiling of GS-9350, A Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects In Vitro
		Christian Callebaut, Luong Tsai, Kirsten Stray, Hongtao Liu, Lianhong Xu, Manoj Desai, Tomas Cihlar
		Gilead Sciences, Foster City, CA, USA
	56.	Production and Characterization of a Highly Infectious Genotype 1B/2A Chimeric Hepatitis C Virus in Cell Culture
		Katie Chan, Huiling Yang, Guofeng Cheng, Maria Pokrovskii, Matthew Paulson, Andrew Greenstein, Hongmei Ho, William Delaney
		Gilead Sciences, Inc., Foster City, CA, USA
	57.	Excision of HIV-1 Proviral DNA Using Tre-recombinase: An Experimental Update
		Jan Chemnitz1, Patrick Ziegler2, Ilona Hauber1, Claus-Henning Nagel1, Helga Hofmann-Sieber1, Markus Manz3, Frank Buchholz4, Joachim Hauber1
		1Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany; 2Institute for Research in Biomedicine, Bellinzona, Switzerland; 3University Hospital Zurich, Zurich, Switzerland; 4Max-Planck-Institute for Molecular Cell Biology and Genetics, Dresden, Germany
	58.	Small Molecules Targeting Protein–Protein Interactions: A Promising Anti-HIV Strategy
		Alba Chimirri1, Laura De Luca1, Stefania Ferro1, Rosaria Gitto1, Anna Maria Monforte1, Stefano Agnello1, Maria Letizia Barreca2, Frauke Christ3, Zeger Debyser3
		1Department of Medicinal Chemistry, University of Messina, Messina, Italy; 2Department of Pharmaceutical Chemistry and Technology, University of Perugia, Perugia, Italy; 3Mol. Virology and Gene Therapy Mol. Medicine, Katholieke Universiteit Leuven and IRC KULAK, Leuven, Belgium
	59.	A Cell Protection Screen Reveals Potent Inhibitors of Multiple Stages of the Hepatitis C Virus Life Cycle
		Karuppiah Chockalingam1, Rudo Simeon1, Charles Rice2, Zhilei Chen1
		1Texas A&M University, College Station, TX, USA; 2Rockefeller University, New York City, NY, USA
	60.	Synthesis and Tissue Distribution Studies of Acyloxyalkyl Prodrug Derivative of an Anti-HBV Dinucleotide
		John Coughlin1, Kathleen O’Loughlin2, Sung Rhee2, Mary Tanga2, Radhakrishnan Iyer1, Anna Furimsky2, Seetharamaiyer Padmanabhan1, Judith Marquis3, Amy Ta2, Carol Green2, Jon Mirsalis2
		1Spring Bank Pharmaceuticals, Inc., Milford, MA, USA; 2SRI International, Menlo Park, CA, USA; 3Genzyme Corporation, Cambridge, MA, USA
	61.	CYSTUS052, A New Compound against Seasonal and Pandemic Influenza Virus
		Karolin Droebner1, Christina Ehrhardt2, Stephan Ludwig2, Oliver Planz1
		1Friedrich-Loeffler-Institut, Institute of Immunology, Tübingen, Germany; 2Institute of Molecular Virology (IMV), University of Münster, Münster, Germany
	62.	Lectins and T-20, But not Neutralizing Antibodies, Inhibit HIV-1 Env-Mediated Syncytium Formation Between Clone69T1RevEnv and SupT1 Cells Monitored by Fluorescence Microscopy
		Nejat Düzgüneş1, Michael Yee1, Jan Balzarini2, Krystyna Konopka1
		1Department of Microbiology, University of the Pacific Arthur A. Dugoni School of Dentistry, San Francisco, CA, USA; 2Rega Institute for Medical Research, Catholic University of Leuven, Leuven, Belgium
	63.	CYSTUS052, A Polyphenol Rich Plant Extract, Exerts Potent Antiviral Activity against Influenza- and Rhinoviruses by Preventing Viral Attachment to Host Cells
		Christina Erhardt1, Eike Hrincius1, Anne Poetter2, Karoline Droebner3, Oliver Planz3, Stephan Ludwig1
		1FLI, Tuebingen, Germany; 2IMV/ZMBE, Muenster, Germany; 3Dr. Pandalis Urheimische Medizin, Glandorf, Germany
	64.	Withdrawn
		Juliane Gentzsch1, Clarence R. Hurt2, Vishwanath R. Lingappa2, Thomas Pietschmann1
		1Department of Experimental Virology, TWINCORE, Hannover, Germany; 2Prosetta Bioconformatics, San Francisco, CA, USA
	65.	Development of Resistance to the Natural HIV-1 Entry Virus Inhibitory Peptide (VIRIP)
		Emmanuel Gonzalez, Maria Pau Mena, Mercedes Armand-Ugon, Ester Ballana, Bonaventura Clotet, Jose Esté
		IrsiCaixa, Badalona, Spain
	66.	Single-dose Intranasal Delivery with DEF201 (Adenovirus Vectored Mouse Interferon-α) Protects against Phlebovirus and SARS Coronavirus Challenge
		Brian Gowen1, Dale Barnard1, Min-Hui Wong1, Deanna Larson1, Josh Wu2, Jane Ennis3, John Morrey1, Jeffery Turner3
		1Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Logan, UT, USA; 2Defence R&D Canada – Suffield, Medicine Hat, AB, Canada; 3Defyrus Inc., Toronto, ON, Canada
	67.	Evaluation of the Contribution of Amantadine, Ribavirin, and Oseltamivir in a Triple Combination Antiviral Drug (TCAD) Regimen to Suppressing the Emergence of Resistance using a Novel Quantitative Approach
		Justin Hoopes1, Minh Le3, Elizabeth Driebe2, Erin Kelley2, David Engelthaler2, Amy Patick3, Jack Nguyen3
		1Utah State University, Logan, UT, USA; 2TGen North, Flagstaff, AZ, USA; 3Adamas Pharmaceuticals, Emeryville, CA, USA
	68.	Orally Bioavailable Anti-HBV Dinucleotide Acyloxyalkyl Prodrugs
		Radhakrishnan Iyer1, John Coughlin1, Cassandra Kirk1, Seetharamaiyer Padmanabhan1, Brent Korba2, Kathleen O’Loughlin3, Carol Green3, Jon Mirsalis3, John Morrey4
		1Spring Bank Pharmaceuticals, Inc., Milford, MA, USA; 2Georgetown University, Rockville, MD, USA; 3SRI International, Menlo Park, CA, USA; 4Utah State University, Logan, UT, USA
	69.	Activation of Retinoic Acid Inducible Gene (RIG-I) by Nucleotide Analogs: A Potential Novel Mechanism for Antiviral Discovery
		Radhakrishnan Iyer1, John Coughlin1, Seetharamaiyer Padmanabhan1, Brent Korba2, Sua Myong3
		1Spring Bank Pharmaceuticals, Inc., Milford, MA, USA; 2Georgetown University, Rockville, MD, USA; 3University of Illinois, Urbana-Champaign, IL, USA
	70.	Efficacy of 2′-C-Methylcytidine against Yellow Fever Virus in a Hamster Model of Disease
		Justin Julander1, Ashok Jha2, Jung-Ae Choi1, Don Smee1, John Morrey1, Chung Chu2
		1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2The University of Georgia, College of Pharmacy, Athens, GA, USA
	71.	Immunosafety Assessment of CD4 mAb-based Bifunctional HIV Entry Inhibitor (CD4-BFFI) using In Vitro Immunoassays
		Ford Kirschenbaum1, Sandhya Bohini1, Harald Kropshofer2, Nick Cammack1, Surya Sankuratri1, Changhua Ji1
		1Roche Palo Alto, Palo Alto, CA, USA; 2Roche Basel, Basel, Switzerland; 3CA, USA
	72.	Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication in a Lethal SARS-CoV BALB/c Mouse Model by Stinging Nettle Lectin, Urtica Dioica Agglutinin (UDA).
		Yohichi Kumaki, Miles K. Wandersee, Kevin W. Bailey, Aaron J. Smith, Craig W. Day, Jason R. Madson, Donald F. Smee, Dale L. Barnard
		Institute for Antiviral Research, Utah State University, Logan, UT, USA
	73.	Viprolaxikine, A Novel Cytokine-like Protein from Insect Cell Cultures Can Reduce Dengue-2 Virus Titres in Mammalian Cells
		Chaowanee Laosutthipong, Timothy Flegel
	74.	The Susceptibility of Isolates of Pandemic 2009 H1N1 Influenza A Virus to Russian Domestic antivirals
		Irina Leneva1, Alesya Romanovskaya2, Elena Burtseva3, Mike Eropkin4, Alexander Shestopalov2
		1Centre of Chemistry of Drugs, Moscow, Russia; 2Center of Virology and Biotechnology “Vector”, Novosibirsk, Russia; 3D.I. Ivanovsky Institute of Virology, Moscow, Russia; 4Institute of Influenza, St.-Petersburg, Russia
	75.	Small Molecule Inhibitors of De Novo Cell-free Capsid Assembly Effective against Flaviviridae and Togaviridae
		Vishwanath R. Lingappa1, Juliane Gentzsch2, Kiel Copeland1, I.-Ting Jaing1, Michael Corpuz1, Pamela Glass3, Jaisri R. Lingappa4, Brenna Kelley-Clarke4, Debendranath Dey1, Colm Kelleher1, Andy Atuegbu1, Amy Anderson1, Josh Lehrer-Graiwer1, Thomas Pietschmann2, Clarence R. Hurt1, William Hansen1
		1Prosetta Bioconformatics, Inc., San Francisco, CA, USA; 2Division of Experimental Virology, TWINCORE, Hannover, Germany; 3Virology Division, USAMRIID, Ft Detrick, MD, USA; 4Department of Global Health, University of Washington, Seattle, WA, USA
	76.	Anti-influenza Action of Multinutrient Functional Peptide Complex (MFPC) Grinization®
		V. Lozitsky1, I. Gomolyako2, S. Pozdnyakov1, A. Fedchuk1, T. Gridina1, L. Socheslo1, V. Pushkina1, N. Klochkova2, V. Shestakov3
		1Ukrainian Mechnikov Antiplague Research Institute, Odesa, Ukraine; 2The National Institute of Surgery and Transplantology named by A.A.Shalimov, Kyiv, Ukraine; 3The Institute of Health of Nation, Kyiv, Ukraine
	77.	Antiviral Action of Artificial Ribonucleases against Avian & Human Influenza Viruses
		V. Lozitsky1, A. Fedchuk1, T. Grydina1, L. Korolyeva2, V. Sil’nikov2, L. Socheslo1
		1Ukrainian Mechnikov Research Anti-Plague Institute, Odesa, Ukraine; 2Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia
	78.	Efficient Suppression of Human Immunodeficiency Virus in Macrophages by Nano-NRTIs
		Edward Makarov, Trevor Gerson, Thulani Senanayake, Larisa Poluektova, Serguei Vinogradov
		University of Nebraska Medical Center, Omaha, NE, USA
	79.	Oseltamivir Protection of Oxidative Damages in Mice Experimentally Infected by Influenza Virus
		Milka Mileva, Angel S. Galabov
		The Stephan Angeloff Institute of Microbiology, Sofia, Bulgaria
	80.	Discovery and Treatment of Respiratory Neurological Sequelae in West Nile Virus Infected Hamsters
		John D. Morrey1, Venkatraman Siddharthan1, Hong Wang1, Neil E. Motter1, Jeffery O. Hall1, Robert D. Skinner2
		1Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; 2Center for Translational Neuroscience and Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA
	81.	Breaking Tolerance with CLDC-HBsAg in HBV Transgenic Mice
		John D. Morrey1, Jeff Fairman2, Stella Chang2, Neil E. Motter1
		1Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; 2Juvaris BioTherapeutics, Inc., Burlingame, CA, USA
	82.	Pro-drugs of Strand Transfer Inhibitors of HIV-1 Integrase: Inhibition Data, Structure–Activity Analysis and Anti-HIV Activity
		Vasu Nair, Byung Seo, Malik Nishonov, Maurice Okello, Sanjay Mishra
		University of Georgia, Athens, GA, USA
	83.	Triple Combination Antiviral Drug (TCAD) Regimen Composed of Amantadine, Ribavirin, and Oseltamivir Imposes A High Genetic Barrier to the Development of Resistance against Influenza A Viruses In Vitro
		Jack Nguyen1, Justin Hoopes2, Elizabeth Driebe3, Kelly Sheff3, David Engelthaler3, Minh Le1, Amy Patick1
		1Adamas Pharmaceuticals, Emeryville, CA, USA; 2Utah State University, Logan, UT, USA; 3TGen North, Flagstaff, AZ, USA
	84.	Inhibition of Hepatitis C Virus Replication by Semisynthetic Derivatives of Glycopeptide Antibiotics
		Susan Obeid1, Maria N. Preobrazhenskaya2, Leen Delang1, Svetlana S. Printsevskaya2, Eugenia N. Olsufyeva2, Svetlana E. Solovieva2, Jan Balzarini1, Alfons Van Lommel3, Johan Neyts1, Jan Paeshuyse1
		1Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium; 2Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia; 3Department of Morphology and Molecular Pathology, K.U.Leuven, Leuven, Belgium
	85.	Eradication of Persistent Bovine Viral Diarrhea Virus Infection in Cell Culture by Antiviral Treatment: How to Get Ahead of the Viral Evasion Strategy
		Jan Paeshuyse1, Simone Musiu1, Gerhard Puerstinger2, Johan Neyts1
		1Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium; 2University of Innsbruck, Innsbruck, Austria
	86.	N,N′-Bis(1,2,3-Thiadiazol-5-yl)Benzene-1,2-Diamine Targets the HIV-1 Retroviral Nucleocapsid Zinc Fingers
		Christophe Pannecouque1, Beata Szafarowicz2, Natalia Volkova3, Vasiliy Bakulev3, Wim Dehaen4, Yves Mély2, Dirk Daelemans1
		1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium; 2Laboratoire de Biophotonique et Pharmacologie, UMR 7213 du CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67401, Illkirch, France; 3Urals State Technical University, Mira Str.19, Ekaterinburg, Russia; 4Chemistry Department Katholieke Universiteit Leuven, Celestijnenlaan 200F, B-3001 Leuven, Belgium
	87.	In Vitro Combination Studies of ANA598 with Anti-HCV Agents Demonstrate Enhanced Anti-viral Activity
		Rupal Patel, Peggy Thompson, Richard Showalter, James Appleman
		Anadys Pharmaceuticals, Inc., San Diego, CA, USA
	88.	Discovery of Novel Small Molecule Inhibitors of Multiple Influenza Strains in Cell Culture
		Benjamin Petsch1, Clarence R. Hurt2, Beverly Freeman2, Elisabeth Zirdum1, Anupama Ganesh2, Alexandra Schörg1, Anatoliy Kitaygorodskyy2, Yoko Marwidi2, Olivier Ducoudret2, Colm Kelleher2, William Hansen2, Vishwanath R. Lingappa2, Christian Essrich2, Lothar Stitz1
		1Friedrich-Loeffler-Institute, Federal Research Institute for Animal Health, Institute of Immunology, Tübingen, Germany; 2Prosetta Bioconformatics, San Francisco, CA, USA
	89.	Novel Imino Sugars Potently Inhibit HCV Virion Secretion by Targeting Cellular Endoplasmic Reticulum Alpha-glucosidases
		Xiaowang Qu1, Xiaoben Pan1, Jessica Weidner1, wenquan Yu2, Michael Xu2,3, Timothy Block1,2, Ju-Tao Guo1, Jinhong Chang1
		1Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, PA, USA; 2Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, PA, USA; 3Enantigen Therpeutics, Inc., Doylestown, PA, USA
	90.	Antiviral Activity of Attachment Inhibitor against the Pandemic Influenza A (H1N1) Virus
		S. Rak1, O. Pyankova1, A. Chinarev2, A. Tuzikov2, N. Bovin2, A. Agafonov1, O. Demina1, A. Ryzhikov1
		1FSRI SRC VB Vector, Koltsovo, Russia; 2Shemyakin Institute of Bioorganic Chemistry, Moscow, Russia
	91.	Therapeutic Response Guided Interferon Therapy among Patients Chronically Infected with Hepatitis C Virus
		Abida Raza1, Hafsa Aziz1, Naseeb Zaman2, Iqbal Yousuf3, Faateh Din4, Shahnaz Murtaza1, Javed Irfan1, Mukhtar Muhammad2
		1Nuclear Medicine, Oncology & Radiotherapy Institute, Islamabad, Pakistan; 2PMAS Arid Agriculture University, Rwp, Pakistan; 3Pakistan Council for Science & Technology, Isb, Pakistan; 4National Institute of Population Studies, Isb, Pakistan
	92.	The NF-kappaB-Inhibitor SC75741 Efficiently Blocks Influenza Virus Propagation In Vitro and In Vivo without the Tendency to Induce Resistant Virus Variant
		Sarah Reiling1, Karoline Droebner1, Christina Ehrhardt2, Eike Hirinus Hrincius2, Stephan Ludwig2, Oliver Planz1
		1Friedrich-Loeffler-Institut, Institute of Immunology, Tübingen, Germany; 2Institute of Molecular Virology (IMV), University of Münster, Münster, Germany
	93.	Trypsin Digestion of Hepatitis C Virus NS5B Polymerase Exposes A Hinge at the Active Site
		Karen Rigat, Yi Wang, Thomas W. Hudyma, Min Ding, Xiaofan Zheng, Robert G. Gentles, Brett R. Beno, Min Gao, Susan B. Roberts
		Bristol-Myers Squibb, Wallingford, CT, USA
	94.	Neuraminidase Inhibitor Susceptibility of Swine Influenza A Viruses Isolated Between 1981 and 2008 in Germany
		Michaela Schmidtke1, Katja Bauer1, Dominik Topf1, Heike Braun1, Martina Richter1, Kathrin Pfarr1, Ralf Dürrwald2, Michael Schlegel2, Peter Wutzler1
		1Department of Virology and Antiviral Therapy, Jena University Hospital, Jena, Germany; 2IDT Biologika GmbH, Research and Development Department, Dessau, Germany
	95.	Liver Biopsy Tissue—Real Time Polymerase Chain Reaction (RT-PCR) Viral Load is the Only Goldstandarddiagnostic Assay in Inactive Viral Hepatitis Patients
		P. Selvam1, M. Chandramohan1, S.C. Vivekananthan1, D. Sivakumar1, M. Suresh2, P.K. Rath2
		1Kamarajar Liver, Jaundice Hospital & Research Centre, Madurai 625001, India; 2Doctor's Blood Bank & Research Centre, Tiruchirapalli 620018, India
	96.	Design, Molecular Modelling Studies on Isatin Analogues as Novel Inhibitors of HIV Integrase
		P. Selvam1, M. Chandramohan2, N. Saravanan Prabhu3, M. Suresh Kumar3
		1Devaki Amma Memorial College of Pharmacy, Chelembra, Malapuram, Kerala, India; 2Bharat Ratna Kamarajar Liver Hospital and Research Centre, Madurai 625020, India; 3Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Puducherry 605014, India
	97.	Activity of Isatine-Sulphadimidine Derivatives against 2009 Pandemic H1N1 Influenza Virus in Cell Culture
		Periyasamy Selvam1, Markandavel Chandramohan2, Brett L. Hurst3, Donald F. Smee3
		1Devaki Amma Memorial College of Pharmacy, Malapuram, India; 2Bharat Ratna Kamarajar Liver Hospital and Research Centre, Madurai, India; 3Institute for Antiviral Research, Utah State University, Utah, UT, USA
	98.	Studies of HIV Integrase Inhibitory Activity of Morinda Citrifolia L Noni Fruit Extracts
		Periyasamy Selvam1, Kasthuraiah Maddali2, Christophe Marchand2, Yves Pommier2
		1Devaki Amma Memorial College of Pharmacy, Malapuram 676364, India; 2Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, MD 20892, USA
	99.	Synergistic Inhibition of Influenza A Virus Replication by a Bacterial Protease Inhibitor and a Plant Preparation
		Julia Serkedjieva1, Michele Dalgalarrondo2, Iskra Ivanova3
		1Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria; 2Institut National de la Recherche Agronomique-BIA-FIPL, Nantes, France; 3Department of Microbiology, Sofia University, Sofia, Bulgaria
	100.	Optimization of Novel Broad Spectrum Anti-Influenza Therapeutics
		William Severson1, Xi Chen3, Colleen Jonsson1,2,5, Clinton Maddox2, Joseph Maddry3, James Noah1, Stephen Ontiveros1, William Parker1, Donald Smee4
		1Department of Biochemistry, Birmingham, USA; 2SRMLSC, Birmingham, USA; 3Department of Chemistry Southern Research, Birmingham, USA; 4Institute for Antiviral Research, USU, Logan, USA; 5Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, USA
	101.	Humanized Neutralizing Monoclonal Antibody and Cyclosporine Treatment for Motor Unit Number Estimation in West Nile Virus Infected Hamster Model
		Venkatraman Siddharthan1, Brandon Taro1, Hong Wang1, Jeffery Nordstrom2, Jeffery Hall1, Robert Skinner3, John Morrey1
		1Institute for Antiviral Research, Animal Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA; 2MacroGenics, Inc., Rockville, MD, USA; 3Center for Translational Neuroscience and Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA
	102.	Effect of Acridonoacetic Acid on Production of Il-6 in Influenza-infected Peripheral Blood Lymphocytes
		Alexander Slita, Marina Stukova, Vladimir Zarubaev
		Influenza Research Institute, St. Petersburg, Russia
	103.	Efficacy of Combinations of Oseltamivir and Peramivir in Treating Influenza A (H1N1) Virus Infections in Cell Culture and in Mice
		Donald Smee1, Brett Hurst1, Min-Hui Wong1, E. Bart Tarbet1, Y.S. Babu2, John Morrey1
		1Institute for Antiviral Research, Utah State University, Logan, UT, USA; 2Biocryst Pharmaceuticals, Birmingham, AL, USA
	104.	Antiviral Drug Efficacy Evaluation against Pandemic Influenza A (H1N1) Viruses in MDCK Cells
		Bart Tarbet1, Brett Hurst1, Dale Barnard1, Y.S. Babu2, Yousuke Furuta3, Donald Smee1
		1Utah State University, Logan, UT, USA; 2BioCryst Pharmaceuticals, Birmingham, AL, USA; 3Toyama Chemical Co., Toyama, Japan
	105.	In Vitro Combination of ANA598 with other Anti-HCV Agents Can Eliminate the Emergence of Resistant Colonies
		Peggy Thompson, Richard Showalter, Rupal Patel, James Appleman
		Anadys Pharmaceuticals, San Diego, CA, USA
	106.	Development and In Vitro Evaluation of Gel-Formulated Saquinavir as Vaginal Microbicide: Anti-HIV-1 Activity and Pharmaceutical Availability in Biorelevant Media
		Kurt Vermeire1, Joachim Brouwers2, Patrick Augustijns2, Dominique Schols1
		1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Laboratory for Pharmacotechnology and Biopharmacy, Katholieke Universiteit Leuven, Leuven, Belgium
	107.	Identification of Antiviral Activity of Koe-Ken Tang against Influenza Virus
		MingSian Wu, ChiChun Chen, JimTong Horng
		1, Taoyuan, Taiwan
	108.	Anti-influenza Virus Activity by Tricin, Isolated from Sasa Albo-Marginata in Japan
		Kurumi Yazawa1, Yuuzou Tsuchida2, Rie Yamada1, Hidetaka Sadanari1, Tsugiya Murayama1
		1Department of Microbiology and Immunology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan; 2Hououdou Co., Ltd., Tokyo, Japan
	109.	Synthesis and Biological Evaluation of Triazolo-Pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen (HBsAg) Secretion
		Wenquan Yu1,2, Cally Goddard1, Courtney Mills1, Elizabeth Clearfield 1, Andrea Cuconati1, Kang Zhao2, Timothy Block1,3, Xiaodong Xu1
		1Institute for Hepatitis and Virus Research, Doylestown, PA, USA; 2School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China; 3Drexel Institute for Biotechnology and Virology Research, Drexel University, Doylestown, PA, USA
	110.	Anti-influenza Activity of Dihydroquercetin against Lethal Influenza Virus Infection
		Vladimir Zarubaev1, Angela Garshinina1, Nelly Kalinina1, Vadim Anikin1, Vasily Babkin2, Liudmila Ostroukhova2, Oleg Kiselev1
		1Ifluenza Research Institute, St. Petersburg, Russia; 2Irkutsk Institute of Chemistry, Irkutsk, Russia
	111.	Anti-viral Activity of Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) against Lethal Influenza Infection Caused by Pandemic Strain A/California/07/09 (H1N1) Virus in White Mice
		Vladimir Zarubaev1, Vladimir Nebolsin2, Angela Garshinina1, Nelly Kalinina1, Anna Shtro1, Oleg Kiselev1
		1Influenza Research Institute, St. Petersburg, Russia; 2ValentaPharmaceuticals JSC, Moscow, Russia
	112.	Activity of a Novel Fullerene-based Antiviral against Influenza Virus Infection In Vitro and In Vivo
		Vladimir Zarubaev1, Pavel Anfimov1, Anna Shtro1, Lev Rasnetsov2, Oleg Kiselev1
		1Influenza Research Institute, St. Petersburg, Russia; 2Intelpharm GC, Nizhny Novgorod, Russia
Tuesday, April 27, 2010
Poster Session 2: Herpes Viruses, Pox Viruses, Other Antiviral, Medicinal Chemistry and Topical Microbicides
Pacific D-O
04:00 p.m.–06:00 p.m.
	113.	Synthesis and Antiviral Activity of 3-O-Phosphonomethyl Nucleosides
		Michal Cesnek, Piet Herdewijn
		Laboratories of Medicinal Chemistry and Virology, Rega Institute for Medical Research, Minderbroedersstraat 10, Belgium
	114.	Oral Pharmacokinetics of Hexadecyloxypropyl 9-(R)-[2-(Phosphono-Methoxy)Propyl]Guanine (HDP-(R)-PMPG) in Mice using LC/MS/MS
		Kathy A. Aldern1, Julissa Trahan2, James R. Beadle1, Yongxuan Su1, Karl Y. Hostetler1,2
		1University of California, San Diego, La Jolla, CA, USA; 2Veterans Medical Research Foundation, San Diego, CA, USA
	115.	Efficient Synthesis and Biological Properties of Base Substituted 2,4-Diamino-6-(R)-[3-Hydroxy-2-(Phosphonomethoxy)Propoxy]Pyrimidine (HPMPO-DAPy)
		Petra Břehová, Martin Dračínský, Antonín Holý
		Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
	116.	A Single Intranasal Administration of DEF201 Protects against Lethal Respiratory Challenge with Western Equine Encephalitis Viruses
		Tahar Babas1, Elizabeth Peters1, Jocelyn Bassler1, Amy Rippeon1, Ronda Wright1, Ginger Donnelly1, Jane Ennis2, Lowery Rhodes1, Jeffrey Turner2, Peter Silvera1
		1Southern Research Institute, Frederick, MD, USA; 2Defyrus, Inc., Toronto, ON, Canada
	117.	Synthesis and Solution Structure of DNA Duplexes Containing the Potent Anti-poxvirus Agent Cidofovir
		James R. Beadle1, Subhrangsu Chatterjee2, Wendy C. Magee2, Brian D. Sykes2, David H. Evans2, Karl Y. Hostetler1
		1University of California, San Diego, La Jolla, CA, USA; 2University of Alberta, Edmonton, AB, Canada
	118.	Inhibition of Calicivirus Replication in Mammalian Cells by RNAI
		Mirko Bergmann, Jacques Rohayem, Dresden, Germany
	119.	Withdrawn
		Michal Cesnek, Piet Herdewijn
		Laboratories of Medicinal Chemistry and Virology, Rega Institute for Medical Research, Minderbroedersstraat 10, Leuven, Belgium
	120.	Developing Capsid Inhibitor V-073 for Poliovirus
		Marc Collett, Jeffrey Hincks
		ViroDefense Inc., Rockville, MD, USA
	121.	Addition Antiflogistic to Viral Inhibitor
		G. Danilenko1, S. Rybalko2, T. Bukhtiarova3, V. Danilenko3, S. Guzhova1, V. Lozitsky4
		1Institute of Organic Chemistry, Kyiv, Ukraine; 2Institute of Epidemiology and Infectional Diseases, Kyiv, Ukraine; 3Institute of Pharmacology and Toxicology, Kyiv, Ukraine; 4Ukrainian Mechnikov Research Anti-Plague Institute, Odesa, Ukraine
	122.	Unsymmetrical CADA Analogs as Novel Down-modulators of the CD4 Receptor
		Violeta Demillo1, Kurt Vermeire2, Dominique Schols2, Thomas Bell1
		1Department of Chemistry, University of Nevada, Reno, NV, USA; 2Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
	123.	The Discovery and Efficacy of a Small Molecule Inhibitor of Ebola Capsid Assembly in an Animal Model
		Jean Francis1, Warren Kalina3, Travis Warren3, Katie Edwards2, I-ting Jaing1, A. Pia Abola1, Abhar Nissar1, Anatoliy Kitaygorodskyy1, Clarence R. Hurt1, Sina Bavari3, William Hansen1, Vishwanath R. Lingappa1
		1Prosetta Bioconformatics, San Francisco, CA, USA; 2CUBRC, Inc., Buffalo, NY, USA; 3Integrated Toxicology Division, USAMRIID, Ft. Detrick, MD, USA
	124.	Structure–Activity Relationships of d- and l-Analogs of Maribavir and 1-Beta-d-Ribofuranosyl-2-Bromo-5,6-Dichlorobenzimidazole (BDCRB) against Human Herpesvirus 6
		Samuel Frederick1, Shannon Daily1, Kathy Borysko2, Leroy Townsend2, John Drach2, Mark Prichard1
		1The University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA; 2School of Dentistry and College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
	125.	Stereospecific Phosphorylation of Cyclopropavir by pUL97 and Inhibition by Maribavir
		Brian G. Gentry1, Jeremy P. Kamil2, Donald M. Coen2, Jiri Zemlicka3, John C. Drach1
		1University of Michigan, Ann Arbor, MI, USA; 2Harvard Medical School, Boston, MA, USA; 3Wayne State University, Detroit, MI, USA
	126.	Screening and Rational Design of Low Molecular Weight HIV Fusion Inhibitors
		Miriam Gochin1,4, Guangyan Zhou1, Dong Wu1, Landon Whitby2, Dale Boger2, Thomas Chung3
		1Touro University, Vallejo, CA, USA; 2Scripps Research Institute, San Diego, CA, USA; 3Burnham Institute, San Diego, CA, USA; 4University of California, San Francisco, CA, USA
	127.	A New Tacaribe Arenavirus Infection Model to Explore the Antiviral Activity of a Novel Aristeromycin Analog
		Brian Gowen1, Kie-Hoon Jung1, Deanna Larson1, Wei Ye2, John Morrey1, Donald Smee1, Stewart Schneller2
		1Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, USA; 2Chemistry & Biochemistry Department, Auburn University, Auburn, AL, USA
	128.	Metal Complexes of Macrocyclic Polyamines Targeting the Cellular HIV Co-receptors, CXCR4 and CCR5
		Sunil Hamal1, Dana Huskens2, Dominique Schols2, Thomas Bell1
		1Department of Chemistry, University of Nevada, Reno, NV, USA; 2Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
	129.	Changes in Human Cytomegalovirus Transcriptional Patterns Induced by Antiviral Drugs
		Caroll Hartline1, Dirk Dittmer2, John Drach3, Frances Chen1, R. Curtis Hendrickson1, Elliot Lefkowitz1, Mark Prichard1
		1The University of Alabama School of Medicine, Birmingham, AL, USA; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3University of Michigan, Ann Arbor, MI, USA
	130.	Antiviral Activity of Acyclic Nucleoside Phosphonates with Branched 2-(2-Phosphonoethoxy)Ethyl Chain
		Dana Hocková1, Antonín Holý1, Graciela Andrei2, Robert Snoeck2, Jan Balzarini2
		1Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic; 2Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
	131.	Nucleotide Analogs that Induce Cellular Production of Antimicrobial Proteins
		Radhakrishnan Iyer1, John Coughlin1, Seetharamaiyer Padmanabhan1, Brent Korba2, Sua Myong3, Bud Tennant4, John Morrey5
		1Spring Bank Pharmaceuticals, Inc., Milford, MA, USA; 2Georgetown University, Rockville, MD, USA; 3University of Illinois, Urbana-Champaign, IL, USA; 4Cornell University, Ithaca, NY, USA; 5Utah State University, Logan, UT, USA
	132.	Synthesis and Antiviral Evaluation of 3-(2,3-Dihydroxypropyl)Furo[2,3-D]Pyrimidin-2(3H)-Ones
		Zlatko Janeba1, Antonín Holý1, Robert Snoeck2, Graciela Andrei2, Erik De Clercq2, Jan Balzarini2
		1Institute of Organic Chemistry and Biochemistry AS CR, Prague, Czech Republic; 2Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium
	133.	Combating Drug-resistant Influenza Viruses with Novel Green Tea Catechin Derivatives
		Kunihiro Kaihatsu1, Hiroyo Matsumura1, Shuichi Mori1, Chiharu Kawakami2, Hideshi Kurata2, Nobuo Kato1
		1Osaka University, Ibaraki, Japan; 2Yokohama City Institute of Health, Yokohama, Japan
	134.	Small Molecule Therapeutics of Viruses of Families Bunyaviridae and Arenaviridae
		Marcela Karpuj1, Darci Smith2, Brenna Kelley-Clarke3, Andrea Stossel2, Anna Honko2, Sean Broce4, Nessie Van Loan4, Emma Harrell4, Colm Kelleher4, Jaisri R. Lingappa3, William Hansen4, Clarence R. Hurt4, Lisa Hensley2, Vishwanath R. Lingappa4
		1CUBRC, Inc., Buffalo, NY, USA; 2Virology Division, USAMRIID, Ft Detrick, MD, USA; 3Department of Global Health, University of Washington, Seattle, WA, USA; 4Prosetta Bioconformatics, Inc., San Francisco, CA, USA
	135.	Efficacy of N-Methanocarbathymidine against Herpes Simplex Virus is Cell Cycle Dependent
		Kathy Keith1, Emma Harden1, Rachel Gill1, Victor Marquez2, Earl Kern1, Mark Prichard1
		1The University of Alabama School of Medicine, Birmingham, AL, USA; 2National Cancer Institute, Frederick, MD, USA
	136.	Synthesis and Antiviral Activity of Adamantyl Modified Nucleoside Phosphonates: Analogs of Cidofovir
		Yuri Klimochkin, Alexander Reznikov, Michael Skomorokhov, Eugene Golovin
		Samara State Technical University, Samara, Russia
	137.	The Activity of the New Adamantane Derivatives against the Orthopoxviruses
		Yuri Klimochkin1, Vitaliy Osyanin1, Eugene Golovin1, Marina Leonova1, Sergey Konkov1, Natalia Kilyaeva1, Nikolay Bormotov2, Olga Serova2, Sergey Balakhnin2, Eugene Belanov2
		1Samara State Technical University, Samara, Russia; 2FSRI SRC VB “Vector” Rospotrebnadzor, Koltsovo, Novosibirsk reg., Russia
	138.	The Influence of Combined Application of Interferon Inducers with Proteolysis Inhibitor on the Endogenic Interferon Level
		M. Kozlovsky1, V. Lozitsky2, I. Lozynsky1, L. Benzel3
		1Lviv Research Institute of Epidemiology and Hygiene, Lviv, Ukraine; 2Ukrainian I.I.Mechnikov Research Anti-Plague Institute, Odesa, Ukraine; 3Lviv National Medical University named after D.Galitsky, Lviv, Ukraine
	139.	Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-2,6-Diaminopurine (HPMPDAP) as Anti-poxvirus Agents
		Marcela Krecmerova1, Antonin Holy1, Graciela Andrei2, Karel Pomeisl1, Tomas Tichy1, Genevieve Laflamme3, Lieve Naesens2, Tomas Cihlar3, Johan Neyts2, Erik De Clercq2, Jan Balzarini2, Robert Snoeck2
		1Institute of Organic Chemistry and Biochemistry, v.v.i., Gilead Sciences & IOCB Research Centre, Centre for New Antivirals and Antineoplastics, Academy of Sciences of the Czech Republic, Prague, Czech Republic; 2Rega Institute for Medical Research, Katholieke Universiteit, Leuven, Belgium; 3Gilead Sciences, Inc., Foster City, CA, USA
	140.	New Nucleoside and Bis-Nucleoside-Phosphonate Conjugates: Design, Stability, and Anti-HIV Evaluation
		Marina Kukhanova1, Maxim Jasko2, Dmitry Yanvarev3, Inna Karpenko4, Alexander Shipitzyn5, Anastasia Khandazhinskaya6
		1Engelhardt Institute of Molecular Biology, Moscow, Russia; 2Engelhardt Institute of Molecular Biology, Moscow, Russia; 3Engelhardt Institute of Molecular Biology, Moscow, Russia; 4Engelhardt Institute of Molecular Biology, Moscow, Russia; 5Engelhardt Institute of Molecular Biology, Moscow, Russia; 6Engelharln Institute of Molecular Biology, Moscow, Russia
	141.	RNA Polymerase Fidelity Variants of the Picornaviruses Uncover A Novel, Indirect RNA Mutagenic Activity for Amiloride Compounds
		Laura Levi, Nina Gnädig, Stéphanie Beaucourt, Marco Vignuzzi
		Institut Pasteur, Paris, France
	142.	Overlap in Virus Specificity Leads to the Discovery of Small Molecules Active Against Rabies Virus, Cytomegalovirus, and Monkey Pox Virus
		Vishwanath R. Lingappa1, Usha Lingappa1, Eva Borst5, Jacqueline Pajda2, Ian Brown1, Scott Long1, Bhadresh Rami1, Aysegul Nalca3, W. Ian Lipkin4, Charles Rupprecht6, Martin Messerle5, Clarence R. Hurt1, William Hansen1
		1Prosetta Bioconformatics, San Francisco, CA, USA; 2CUBRC, Inc., Buffalo, NY, USA; 3Division of Aerobiological Sciences, USAMRIID, Ft. Detrick, MD, USA; 4Columbia University, New York, NY, USA; 5Hannover Medical School, Hannover, Germany; 6Center For Disease Control and Prevention, Atlanta, GA, USA
	143.	Cell-free Protein Synthesizing Systems as Tools for Discovery of Drugs Inhibiting Viral Capsid Assembly
		Vishwanath R. Lingappa1, Emma Harrell1, Kiel Copeland1, M. Dharma Prasad2, Vinod Asundi1, Nick Hahner1, Jean Francis1, Debendranath Dey1, Jennifer Welsh1, Amanda Macieik1, Jaisri R. Lingappa3, Colm Kelleher1, Clarence R. Hurt1, William Hansen1
		1Prosetta Bioconformatics, Inc, San Francisco, CA, USA; 2Prosetta Bioconformatics Pvt. Ltd., Mysore, India; 3Deptartment of Global Health, University of Washington, Seattle, WA, USA
	144.	A Chemoenzymatic Synthesis of Carbocyclic Nucleosides and Nucleotides
		Miriam Mahler1, Bastian Reichardt1, Jan Balzarini2, Chris Meier1
		1Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
	145.	D-carba-dT as a Promising New Antiviral Compounds?
		Chris Meier1, Bastian Reichardt1, Warnecke Svenja1, Miriam Mahler1, Stephen Hughes2, Paul Boyer2
		1University of Hamburg, Organic Chemistry, Department of Chemistry, Hamburg, Germany; 2NCI-Frederick, Frederick, MD, USA
	146.	QSAR Analysis of Poliovirus Inhibition by Dual Combinations of Antivirals
		Eugene N. Muratov1,2, Ekaterina V. Varlamova1, Victor E. Kuz’min1, Anatoly G. Artemenko1, Lubomira Nikolaeva-Glomb3, Angel S. Galabov3
		1Laboratory of Theoretical Chemistry, A.V.Bogatsky Physical-Chemical Institute NAS of Ukraine, Odessa, Ukraine; 2Laboratory of Molecular Modeling, School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3The Stephan Angeloff Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria
	147.	Anti-human Cytomegalovirus Activity by 4′,5,7-Trihydroxy-3′,5′-Dimethoxyflavone (Tricin)
		Tsugiya Murayama1, Yuuzou Tsuchida2, kurumi Yazawa1, Rie Yamada1, Keiko Matsubara1, Hidetaka Sadanari1
		1Department of Microbiology and Immunology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan; 2Hououdou Co., Ltd., Tokyo, Japan
	148.	In Vitro Investigation of Cytotoxic Action of Hemocyanins on Cell Cultures
		N. Nesterova1, P. Dolashka-Angelova2, S. Zagorodnya1, V. Moshtanska2, G. Baranova1, A. Golovan1, A. Kurova1
		1Institute of Microbiology and Virology UNAS, Kyiv, Ukraine; 2Institute of Organic Chemistry BAS, Sofia, Bulgaria
	149.	The Antienteroviral Effect of Oxoglaucine and Phenotypic Characterization of the Oxoglaucine Resistant Mutant of Coxsackievirus B1
		Lubomira Nikolaeva-Glomb1, Stefan Philipov2, Angel S. Galabov1
		1The Stephan Angeloff Institute of Microbiology, Sofia, Bulgaria; 2Institute of Organic Chemistry with Centre of Phytochemistry, Sofia, Bulgaria
	150.	The Disease Course and Host's Response to Mousepox is Dependent on Inoculation Route
		Scott Parker, Mark Buller
		Saint Louis University School of Medicine, St Louis, MO, USA
	151.	Nucleoside Diphosphate Prodrugs of Antivirally Active Nucleosides
		Florian Pertenbreiter, Chris Meier
		Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany
	152.	Evaluations of Combinations of CMX001 and Ganciclovir against Cytomegalovirus Infections using Real Time PCR
		Mark Prichard1, Caroll Hartline1, Randall Lanier2, Earl Kern1
		1The University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA; 2Chimerix, Inc., Durham, NC, USA
	153.	In Vivo Efficacy of Twice Daily Oral Treatment with N-MCT against Herpes Simplex Virus Type 2 in Balb/c mice
		Debra Quenelle1, Robert Glazer2, Aquilur Rahman2, Deborah Collins1, Terri Rice1
		1The University of Alabama School of Medicine, Birmingham, AL, USA; 2N & N Scientific, Inc., Rockville, MD, USA
	154.	Enhanced Efficacy using Combinations of CMX001 with Acyclovir against Herpes Simplex Virus Infections In Vitro and in Mice
		Debra Quenelle1, Mark Prichard1, Caroll Hartline1, Emma Harden1, Deborah Collins1, Terri Rice1, Randall Lanier2, Earl Kern1
		1The University of Alabama School of Medicine, Birmingham, AL, USA; 2Chimerix, Inc., Durham, NC, USA
	155.	First Diastereoselective Synthesis of Pronucleotides
		Edwuin Rios Morales1, Cristina Arbelo Roman1, Jan Balzarini2, Chris Meier1
		1Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
	156.	L-β-1-(5-Bromovinyl-2-Hydroxymethyl-1,3-Dioxolanyl) Uracil (L-BHDU) Prevents Varicella-Zoster Virus Replication in Fibroblasts, Skin Organ Culture, and SCID-HU Mice with Human Skin Xenografts
		Jenny Rowe1, Robert D. Arnold2, Catherine White2, Jessica Toli1, Chung K. Chu2, Jennifer Moffat1
		1SUNY Upstate Medical University, Syracuse, NY, USA; 2Univ. of Georgia, Athens, GA, USA
	157.	Synthesis and Antiviral Evaluation of Alkoxyalkyl Esters of (R)-[2-(Phosphonomethoxy)Propyl]-Nucleosides
		Jacqueline C. Ruiz1, Kathy A. Aldern2, Julissa Trahan1, James R. Beadle2, Karl Y. Hostetler1,2
		1Veterans Medical Research Foundation, San Diego, CA, USA; 2University of California, San Diego, La Jolla, CA, USA
	158.	Synthesis of Novel CADA Analog Prodrugs Designed as Down-Modulators of the CD4 Receptor
		Emily Scarbrough1, Kurt Vermeire2, Dominique Schols2, Thomas Bell1
		1Department of Chemistry, University of Nevada, Reno, NV, USA; 2Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
	159.	Rational Drug Design—Screening and Synthesis of Potential Deoxyhypusine Synthase Inhibitors Targeting HIV-1 Replication
		Marcus Schroeder1, Adrian Kolodzik2, Bjoern Windshuegel2, Marcel Krepstakies3, Poornima Priyadarshini3, Matthias Rarey2, Joachim Hauber3, Chris Meier1
		1Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; 2Center for Bioinformatics, University of Hamburg, Hamburg, Germany; 3Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany
	160.	Lipophilic Nucleoside Diphosphate Prodrugs—Synthesis and Properties
		Tilmann Schulz1, Jan Balzarini2, Chris Meier1
		1Institute of Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
	161.	Synthesis, Antiviral and Cytotoxicactivities of 2-Phenyl, 3-Substituted Quinazolin-4(3H)-Ones
		Periyasamy Selvam1, Narayanan Murugesh2, Markandavel Chandramohan3, CHRISTOPHE Panpannecouque4, Erick De Clercq4
		1Devaki Amma Memorial College of Pharmacy, Malapuram, India; 2Institute of Pharmacology, Madurai Medical College, Madurai, India; 3Bharat Ratna Kamarajar Liver Hospital and Research Centre, Madurai, India; 4Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
	162.	Synthesis of a Series of 2′-modified Tricyclic Nucleosides as Potential HCV Agents
		Matthew Tomney1, Brent Korba2, Sarah Zimmermann1, Katherine Seley-Radtke1
		1University of Maryland Baltimore County, Baltimore, MD, USA; 2Georgetown University Medical Center, Washington, DC, USA
	163.	Acute Toxicity of Oral Octadecyloxyethyl Esters of 3-Hydroxy-2-(Phosphonomethoxy) Propyl Nucleosides in Balb/c Mice
		Julissa Trahan1, Nadejda Valiaeva1,2, James Beadle1,2, Karl Hostetler1,2
		1Veterans Medical Research Foundation, San Deigo, CA, USA; 2University of California San Diego Dept. of Medicine, La Jolla, CA, USA
	164.	Cidofovir: Intratympanic Delivery and Hearing Loss
		Jonette Ward1, Alisa Reece1, Kevin Li2, Daniel Choo1
		1Center for Hearing and Deafness Research, CCHMC, Cincinnati, OH, USA; 2College of Pharmacy, UC, Cincinnati, OH, USA
	165.	Toward A More Complete Anti-herpesvirus SAR for 2nd Generation Methylenecyclopropane Nucleosides
		John D. Williams1, Atiyya R. Khan1, Mark N. Prichard2, Sam L. Frederick2, Geraldine M. Jefferson2, Jiri Zemlicka3, Norton P. Peet1, Terry L. Bowlin1
		1Microbiotix, Inc., Worcester, MA, USA; 2University of Alabama at Birmingham, Birmingham, AL, USA; 3Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
	166.	Stereoselective Synthetic Strategy to Potentially Antiviral Active Carbocyclic l-Nucleosides and l-Nucleotides
		Claudia Worthmann1, Sönke Jessel1, Jan Balzarini2, Chris Meier1
		1Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; 2Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
	167.	A Novel Fullerene-based Antiviral Active against Herpes Simplex Virus In Vitro and In Vivo
		Vladimir Zarubaev1, Alexander Slita1, Lev Rasnetsov2, Pavel Anfimov1
		1Influenza Research Institute, St. Petersburg, Russia; 2Intelpharm GC, Nizhny Novgorod, Russia
	168.	Overview on Clinical Trials and Resistance Breaking Activity of the Anti-cytomegalovirus Compound AIC246
		Holger Zimmermann1, Susanne Stoelben1, Dirk Kropeit1, Peter Lischka1, Detlef Michel2, Lutz Renders3, Klemens Budde4, Wolfgang Arns5, Helga Ruebsamen-Schaeff1
		1AiCuris GmbH&CoKG, Wuppertal, Germany; 2Inst. of Virology, University Ulm, Ulm, Germany; 3University of Kiel, Kiel, Germany; 4University Hospital Charite, Berlin, Germany; 5Merheim Medical Center, Köln, Germany